Occurrence and clinicolaboratory profile of mycoplasma infection in children hospitalized with lower respiratory tract infection – A prospective study by Jadala, Hareesh Vardhan & K, Raghavendra
Online First Indian J Child Health 1
Original Article
Occurrence and clinicolaboratory profile of mycoplasma infection in children 
hospitalized with lower respiratory tract infection – A prospective study
Hareesh Vardhan Jadala1, Raghavendra K2
From 1Post Graduate, 2Associate Professor, Department of Paediatrics, Basaveshwara Medical College Hospital and Research Centre, Chitradurga, 
Karnataka, India
Correspondence to: Dr. Raghavendra K, Department of Paediatrics, Basaveshwara Medical College Hospital, Chitradurga - 577 501, 
Karnataka, India. E-mail: anaghawatson@gmail.com
Received - 14 October 2019 Initial Review - 01 November 2019 Accepted - 08 November 2019
Pneumonia, defined as the inflammation of lung parenchyma, is the leading infectious cause of death globally among children younger than 5 years. Pneumonia 
accounted for 15% of all deaths of children under 5 years of 
age in 2017 [1]. Viruses, atypical microorganisms, and bacteria 
cause the vast majority of childhood pneumonia [2-4]. It can be 
difficult to identify whether the cause of pneumonia in a given 
patient is bacterial or non-bacterial [5]. Mycoplasma Pneumoniae 
(MP) accounts for 20–40% of all community acquired pneumonia 
(CAP) among children and adults. Spread is largely through 
school contacts. Secondary attack rate among household members 
is 40% [6].
MP typically presents with sore throat, hoarseness of voice, 
and fever with dyspnea occurring in severe cases. Symptoms can 
persist for weeks to months. Children under 5 years of age are 
most likely to manifest coryza and wheezing, and progression to 
pneumonia is relatively uncommon, whereas older children aged 
5–15 years are more likely to develop bronchopneumonia in one 
or more lobes. Chest auscultation may show scattered or localized 
rhonchi [7,8]. Extrapulmonary manifestations occur in 25% of 
children with MP infection. They may occur from 3 days of onset 
of illness to 3 weeks after resolution.
The most common and life threatening are the neurological 
manifestations such as meningoencephalitis and Guillain–Barré 
syndrome [9], followed by Stevens–Johnson syndrome, erythema 
multiforme, and toxic epidermal necrolysis [10]. Hematological 
manifestations include autoimmune hemolytic anemia, 
autoimmune thrombocytopenia, and disseminated intravascular 
coagulation. Clinical diagnosis of MP infection is difficult due 
to non-specific signs and symptoms. The most common finding 
on chest X-ray is an interstitial infiltrate followed by alveolar 
infiltrates and sometimes pleural effusion [11]. Computed 
tomography chest may show bronchial wall thickening [12].
Cultures require specialized techniques and are positive in 
only 30–60% [13]. Therefore, serological testing is the most 
common means of diagnosing MP infection. The “gold standard” 
is a demonstration of a 4-fold rise in antibody titers [14]. Cold 
agglutinins and complement fixation tests have poor sensitivity 
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and specificity [15,16]. Enzyme immunoassays on paired 
samples have high sensitivity (92%) and specificity (95%) and 
are comparable to polymerase chain reaction (PCR). However, 
it may be positive in asymptomatic carriers [17]. Hence, a 
combination of PCR and immunoglobulin M (IgM) enzyme-
linked immunosorbent assay (ELISA) is considered to be a useful 
approach in children [18].
Although fluoroquinolones and tetracyclines are effective 
against MP, macrolides, especially azithromycin, are the 
preferred antibiotic in children [19]. Macrolide resistance has 
been noted recently, but treatment failure is unlikely even in 
macrolide-resistant infections [20]. This study was done to 
determine the occurrence, clinical features, and laboratory profile 
of MP infection in children presenting with lower respiratory tract 
infection (LRTI).
MATERIALS AND METHODS
This hospital-based descriptive study was done in the department 
of pediatrics of a tertiary care hospital in South India. Institutional 
Ethical Committee clearance was taken before the commencement 
of the study. The study was conducted from November 2014 
to April 2016. The participants consisted of children aged 
1 month–18 years, admitted with LRTI. Seriously ill patients 
requiring mechanical ventilation, children whose parents did not 
give consent or were unwilling for mycoplasma IgM antibody 
testing or children who were known cases of bronchial asthma 
were excluded from the study. Informed consent was obtained 
from the parents and assent of children was taken before the study.
Sampling technique used was non-probability purposive 
sampling technique. History was collected using a pre-tested semi-
structured questionnaire. After a thorough physical examination, 
participants were subjected to routine laboratory investigations. 
Blood sample for mycoplasma IgM ELISA was collected in the 
2nd week of illness. LRTI was considered in the presence of fever 
along with cough and either of the following; fast breathing, 
respiratory distress (chest retractions, grunting, and flaring of ala 
nasi), and crepitations or wheeze. MP infection was considered in 
children tested positive for mycoplasma IgM. Based on the WHO 
classification, stunting was defined as height for age <−2 standard 
deviation (SD) and wasting as a weight for height <−2SD.
The data collected were compiled in MS Excel and analyzed 
using SPSS.V.16.0. Continuous variables were expressed in the 
mean and SD, categorical data are expressed in number and 
percentage. Chi-square test was applied to test the significance of 
association and p<0.05 was considered as statistically significant.
RESULTS
A total of 268 children participated in the study. There was a 
preponderance of males with 151 males (56.3%) and 117 females 
(43.7%); although, the difference was not statistically significant, 
as shown in Table 1.
The clinical features, nutritional status, and chest X-ray 
findings are discussed in Table 2. MP infection was present 
in 41 (15.3%) children out of 268 children with LRTI. The 
occurrence of MP infection was minimal (2.15%) in children 
<3 years. Among children with MP infection, 17 (41.5%) were 
female and 24 (58.5%) were male. This difference was not 
statistically significant (Table 2).
All children had a fever and cough. The average duration 
of fever was 3.5 days (range: 1–10 days). MP infection was 
strongly associated with fever >3 days duration (p=0.025). 
Average duration of cough was 3.16 days (range: 1–12 days). 
No significant association was noticed between cough and MP 
infection. Although wheezing was found to be more common in 
MP-positive group, difference was not statistically significant 
(p=0.07). In the study population, malnutrition as per the WHO 
classification was seen in 17.5%. Wasting was observed in 
15.2% and stunting in 2.2% of children. A greater percentage 
of malnourished children (29.4%) suffered from MP infection 
compared to those with normal nutrition (13.1%). This association 
was found to be statistically significant (p=0.03) (Table 2).
Chest X-ray abnormalities were seen in 69.4% of the study 
population (Table 2). There was no statistically significant 
difference in X-ray patterns between MP-positive and negative 
groups. The findings on complete blood count also showed no 
significant association with MP infection.
DISCUSSION
The occurrence of MP infection among children with LRTI 
was 15.3% in our study. There was no statistically significant 
difference in occurrence between males (56.3%) and females 
(43.7%). Kashyap et al. [21] reported an incidence rate of 
24% among 75 children with CAP, using a combination of 
culture/serology and PCR. Shenoy et al. [22] used mycoplasma 
IgM ELISA and reported an incidence of 24% among children 
hospitalized for pneumonia. Chaudhry et al. [23] reported 27.4% 
MP seropositivity among children with CAP. None of the earlier 
studies have documented a gender preference.
Detection of IgM in a single serum sample for diagnosis 
of MP infection is considered significant in children who had 
fewer opportunities for repeated exposure [24]. Nadal et al. 
compared mycoplasma IgM serology with paired serology and 
found its sensitivity and specificity to be 78.1% and 87.1%, 
respectively [25]. Chang et al. used reverse transcription PCR as a 
standard and found sensitivity and specificity of IgM serology to 
be 62.2% and 85.5%, respectively [26]. In our study, mycoplasma 
IgM ELISA was positive in 41 children (15.3%). As sensitivity of 
the test is determined by timing of specimen collection, we had 
ensured that sera were taken in the 2nd week of illness. However, 
as shown in the study by Kashyap et al., a combination of paired 
serum samples for IgM and IgG in combination with PCR is 
ideal [21]. However, this was not possible in our study due to 
financial constraints.
In our study, the frequency of MP infection was the highest in 
9–12 years (30%) followed by 6–9 years (25.4%) and 3–6 years 
(21.7%) age group and the difference was significant (p=0.001). 
The significant finding here is the high frequency of MP infection 
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in the 3–6 years age group because MP infection is considered to 
rarely affect children <5 years of age [6]. In a study by Shenoy 
et al., the highest incidence was in the 2–5 years and 5–10 years 
age group [22]. This finding is also supported by other studies 
from the Western world [27]. However, Kashyap et al. did not 
find a significant difference in incidence of <5 years and >5 years 
age group [21].
In our study, none of the clinical signs and symptoms showed 
any significant association with MP infection, though wheezing 
was found to be more common in the MP-positive group. One 
significant finding in our study was the association of malnutrition 
with MP infection. A greater percentage of malnourished children 
suffered from MP infection compared to those with normal 
nutrition (p=0.03). Extrapulmonary complications were not 
seen in our study. Other studies have reported 25% incidence of 
extrapulmonary manifestations [7,9,10].
In our study, the only X-ray finding observed in MP infection 
was lobar consolidation (78%). Hyperinflation and patchy 
infiltration were seen only in the MP-negative group. There was no 
significant association between X-ray findings and MP infection. 
In the study by Puljiz et al., chest X-ray abnormalities included 
interstitial infiltrate (90.48%), alveolar infiltrates (8.84%), and 
pleural effusion (8.84%) [11]. In the study by Kashyap et al., 
the X-ray findings were infiltrates (34.67%), hyperinflation 
Table 1: Age and sex distribution of the study population
Character Number (%) MP negative (%) MP positive (%) p value
Age group (years)
Up to 3 93 (34.7) 91 (97.8) 2 (2.15) 0.001
3.1–6 69 (25.7) 54 (78.3) 15 (21.7)
6.1–9 63 (23.5) 47 (74.6) 16 (25.4)
9.1–12 20 (7.46) 14 (70) 6 (30)
>12 23 (8.58) 21 (91.3) 2 (8.7)
Total 268 (100) 227 (84.7) 41 (15.3)
Age (months)* 59.9±48.3 86.9±38.1 0.001
Sex
Female 117 (43.6) 100 (85.5) 17 (14.5) 0.75 
Male 151 (56.34) 127 (84.1) 24 (15.9)
Total 268 (100) 227 (84.7) 41 (15.3)
*Independent t-test. MP: Mycoplasma pneumoniae
Table 2: Clinical features, nutritional status, and chest X‑ray findings in the study population
Parameters MP negative, n (%) MP positive, n (%) Total, n (%) p value
Fever (days)
1–3 142 (88.7) 18 (11.25) 160 (60) χ2=5.022
p=0.025>3 85 (78.7) 23 (21.3) 108 (40)
Cough (days)
1–3 166 (84.7) 30 (15.3) 196 (73.1) χ2=0
p=0.99>3 61 (84.7) 11 (15.3) 72 (26.9)
Respiratory distress
Present 132 (87.4) 19 (12.6) 151 (56.34) χ2=1.96
p=0.16Absent 95 (81.2) 22 (18.8) 117 (43.65)
Wheezing
Present 184 (82.9) 38 (17.1) 222 (82.8) χ2=3.30
p=0.07Absent 43 (93.5) 3 (6.5) 46 (17.2)
Nutritional status
No malnutrition 192 (86.9) 29 (13.1) 221 (82.5) χ2=4.61
p=0.03Malnutrition 35 (74.47) 12 (25.5) 47 (17.5)
Chest X-ray findings*
Normal 73 (89) 9 (11) 82 (30.6) χ2=1.7039
p=0.1917Lobar 
consolidation
109 (77.3) 32 (22.7) 141 (52.6)
Hyperinflation 37 (100) 0 (0) 37 (13.8)
Patchy infiltration 8 (100) 0 (0) 8 (3)
Total 227 (84.7) 41 (15.3) 268 (100)
*Pooled Chi-square test is applied. MP: Mycoplasma pneumoniae
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(26.67%), consolidation (25.33%), and bronchopneumonia 
(17.33%) [21]. Blood counts showed no significant difference 
between the MP-positive and negative groups.
Our study has several limitations. Accurate diagnosis of MP 
infection requires a combination of serology and PCR. However, 
PCR was not used due to financial constraints. Attempt could 
have been made to isolate other etiological agents as MP can 
coinfect with other organisms.
CONCLUSION
MP infection is traditionally considered to be rare in children 
<5 years of age. However, our study showed a significant 
occurrence of MP infection in the 3–6 years age group. The 
clinical, radiological, and hematological findings in MP infection 
are non-specific necessitating empirical treatment with macrolide 
antibiotics in children more than 3 years of age.
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